Your Messages Inbox (38) 
Your Unread Messages
See All
Tracy Hampton, PhD
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions
Cancer Prevention Research, 11/09/09
Tsaoet AS et al. – Epidemiologic and preclinical data support the oral cancer prevention potential of green tea extract (GTE).
Methods- Randomly assigned patients with high-risk oral premalignant lesions (OPL) to receive GTE at 500, 750, or 1,000 mg/m2 or placebo TID for 12 weeks, evaluating biomarkers in baseline and 12-week biopsies
- OPL clinical response rate higher in all GTE arms (n = 28; 50%) versus placebo (n = 11; 18.2%) but did not reach statistical significance
- 2 higher-dose GTE arms [58.8% (750 and 1,000 mg/m2), 36.4% (500 mg/m2), and 18.2% (placebo)] had higher responses, suggesting dose-response effect
- GTE treatment improved histology (21.4% versus 9.1%), although not statistically significant
- GTE well tolerated, although higher doses increased insomnia/nervousness but produced no grade 4 toxicity
- Higher mean baseline stromal vascular endothelial growth factor (VEGF) correlated with a clinical but not histologic response
- Baseline scores of other biomarkers (epithelial VEGF, p53, Ki-67, cyclin D1, and p16 promoter methylation) not associated with response or survival
- Baseline p16 promoter methylation (n = 5) associated with shorter cancer-free survival
- Stromal VEGF and cyclin D1 expression downregulated in clinically responsive GTE patients and upregulated in nonresponsive patients at 12 weeks (versus at baseline)
- Extended (median, 27.5 months) follow-up showed a median time to oral cancer of 46.4 months
Today in Alternative Therapies...keeping you current
Receive free subspecialty "5-minute updates" via email
A phase 2 trial exploring the effects of high-dose (10,000 IU/day) Vitamin D3 in breast cancer patients with bone metastases
Cancer, 11/18/09
Oral Cancer Prevention Advances with a Translational Trial of Green Tea
Cancer Prevention Research, 11/11/09
Complementary and alternative medicine use among long-term lymphoma survivors: A pilot study
American Journal of Hematology, 11/10/09
Today in Head and Neck...keeping you current
Receive free subspecialty "5-minute updates" via email
Mobile Phone Use and Risk of Tumors: A Meta-Analysis
Journal of Clinical Oncology, 10/20/09
Thyroid lymphoma and airway obstruction – is there a rationale for surgical management?
International Journal of Clinical Practice, 10/19/09
Primary extranodal marginal zone lymphoma of the uvea associated with massive diffuse epibulbar extension and focal infiltration of the optic nerve and meninges, clinically presented as uveitis masquerade syndrome: a case report
Medical Oncology, 10/16/09
Sponsor
Article Search
Sponsor
Sponsor